《韩国先驱报》:冠状病毒疫苗还有很长的路要走

2020-02-03 不详 MedSci原创m

《韩国先驱报》援引专家的话表示,任何用于2019年新型冠状病毒的疫苗都不太可能在很短的时间内生产出来。

《韩国先驱报》援引专家的话表示,任何用于2019年新型冠状病毒的疫苗都不太可能在很短的时间内生产出来。

一位疫苗公司雇员说:"即使政府对药物开放快速通道的开发许可,也将花费一年多的时间。"

"因为冠状病毒是RNA病毒,存在高度变异的可能性,意味着该病毒可能会不断转化以使疫苗失效,因而难以破解杀死该病毒的密码。等到疫苗研发出来,病毒可能已经消散。"

新闻来源指出,自2015年韩国爆发中东呼吸综合症至今已经五年,尚未开发出针对性的疫苗。

据消息来源称,同样的冠状病毒会再次发生的可能性很小,这意味着"制药公司可能是跳入一次性项目的投资而没有明确的回报"。

原始出处:

http://www.firstwordpharma.com/node/1697769?tsid=4#axzz6CtgmFGIr

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2083313, encodeId=f6dc20833130b, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sat Feb 08 06:54:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334876, encodeId=f4c413348e617, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 05 12:54:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048151, encodeId=ee292048151d2, content=<a href='/topic/show?id=d017100024b5' target=_blank style='color:#2F92EE;'>#韩国先驱报#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100024, encryptionId=d017100024b5, topicName=韩国先驱报)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Mar 06 03:54:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2083313, encodeId=f6dc20833130b, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sat Feb 08 06:54:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334876, encodeId=f4c413348e617, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 05 12:54:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048151, encodeId=ee292048151d2, content=<a href='/topic/show?id=d017100024b5' target=_blank style='color:#2F92EE;'>#韩国先驱报#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100024, encryptionId=d017100024b5, topicName=韩国先驱报)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Mar 06 03:54:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2083313, encodeId=f6dc20833130b, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sat Feb 08 06:54:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334876, encodeId=f4c413348e617, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 05 12:54:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048151, encodeId=ee292048151d2, content=<a href='/topic/show?id=d017100024b5' target=_blank style='color:#2F92EE;'>#韩国先驱报#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100024, encryptionId=d017100024b5, topicName=韩国先驱报)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Mar 06 03:54:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]